Takeda, Astellas-Pandion, I-Mab and more—FiercePharmaAsia by Angus Liu Friday, November 1, 2019 Takeda's rare disease sales dropped sharply. Astellas teamed with Pandion on Type 1 diabetes. Shanghai's I-Mab filed for a $100 million Nasdaq IPO.
Takeda's rare disease unit suffers on hemophilia, Natpara recall by Angus Liu Thursday, October 31, 2019 Worries about competition to Shire's bread-and-butter hemophilia franchise were clear even before Takeda bought it. That fear has become reality.
Recall of Takeda's Natpara shows pharma fault line by Eric Palmer Monday, September 16, 2019 The recall of Takeda's orphan drug Natpara for hypoparathyroidism illustrates one of the paradoxes of modern drug development. Patients explain.
Takeda recalls Natpara but warns patients by Eric Palmer Friday, September 6, 2019 Takeda is having to recall the Natpara from the market, a move it says may be very challenging for patients.
Takeda tags a third Shire drug for sale to win EU deal approval by Angus Liu Monday, October 29, 2018 Amid reports that it will sell Shire's Xiidra and Natpara, Takeda said it may sell SHP647, a phase 3 bowel drug that would overlap its own Entyvio.
Takeda eyes Shire product sales to pay down debt: Bloomberg by Eric Sagonowsky Friday, September 14, 2018 Takeda hasn't closed its Shire buyout, but it's already thinking about which products to offload to pay down debt, according to Bloomberg.
